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Abstract  
Introduction: Cancer cachexia is a condition often seen at diagnosis, throughout chemotherapeutic 
treatments and in end stage Non-Small Cell Lung Cancer patients. These patients often experience a 
shorter life-expectancy and deterioration in performance status and reduced quality of life. New 
multi˗targeted regimens are required to be tested in this population to address these issues. 
Materials and methods: The ACCeRT study is an open label, prospective, randomised controlled 
feasibility study investigating the use of eicosapentaenoic acid and COX-2 inhibitor (celecoxib) versus 
eicosapentaenoic acid, COX-2 inhibitor (celecoxib), progressive resistance training followed by 
ingestion of essential amino acids high in leucine in Non-Small Cell Lung Cancer cachectic patients. 
The study protocol was published in November 2011. Due to study participants and study team 
preferences a number of changes were made. Firstly, a change from a bolus drink containing 20 g of 
essential amino acids to an encapsulated form in divided doses over three days. Secondly, a change in 
leg strength analysis from utilising a leg/back dynamometry to a customised chair with a load cell 
testing extension isometric force. Thirdly, study drug dose reductions were now permitted. Fourthly, 
addition of two study sites which allowed participants to attend progressive resistance training sessions 
in their local area. Finally, a change in inclusion criteria to include participants that had received any 
first-line anti-cancer treatment. A guest participant was invited onto the study in April 2012, followed 
by the first study participant in June 2012. 
Results: The guest participant showed trends in efficacy in a number of outcomes; stable fat free mass 
in the context of decreasing total body weight, with stable FAACT˗PWB, MFSI-SF physical, and 
WHOQOL-BREF QOL scores at week 20, all during documented disease progression now termed 
refractory cachexia. There were no treatment or exercise-related adverse events. 
Conclusion: Publishing feasibility study protocols allows transparency in study interventions and 
assessments. The above ACCeRT regimen stabilised fat free mass and a number of 
physical/performance indicators and QOL in the guest participant. 
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Introduction 
While the definition of cancer cachexia has 
developed over the years (1-3), it is 
commonly referred to as a “multifactorial 
syndrome defined by an ongoing loss of 
skeletal muscle mass (with or without loss 
of fat mass) that cannot be fully reversed by 
conventional nutritional support and leads 
to progressive functional impairment”, and 
now incorporates the development of the 
stages of cachexia including pre-cachexia, 
cachexia and refractory cachexia (4). 
Notably, the incidence of cachexia is 
tumour type and site dependent, with Non-
Small Cell Lung Cancer (NSCLC) patients 
having documented rates of 61% (5, 6). Of 
clinical importance, cachexia is estimated 
to be present in up to 80% of cancer patients 
at time of death (3). 
Over the last few decades, a number of 
pharmacological agents and methods of 
support have been investigated to address 
the primary areas of cancer cachexia (7). 
Firstly, addressing anorexia via appetite 
stimulation, corticosteroids in the form of 
oral methylprednisolone, prednisolone and 
dexamethasone (8-11), progestinal agents 
in the form of medroxyprogesterone acetate 
and megestrol acetate (12-14), 
cannabinoids in the form of dronabinol 
(15), thalidomide (16), and more recently 
L-carnitine (17). Secondly, addressing 
alterations in energy and substrate 
metabolism in the form of melatonin (18), 
and ghrelin (19). Thirdly, addressing 
skeletal muscle loss via targeting the 
anabolic and catabolic pathways in the form 
of enobosarm (20), espindolol (21, 22), and 
bimagrumab (23). Lastly, addressing 
inflammation in the form of clazakizumab 
(24), and xilonix (MABp1) (25). 
Research addressing cancer cachexia has 
also included multi-targeted approaches 
with the combination of agents (26-28). The 
combination of the anti-cachectic agent 
eicosapentaenoic acid (EPA) and the COX-
2 (cyclo-oxygenase-2) inhibitor celecoxib 
has been tested in a small study of NSCLC 
patients with some benefit (29). While the 
use of progressive resistance training (PRT) 
followed by the oral ingestion of essential 
amino acids (EAA), has been reported to 
provide a potent anabolic stimulus on 
skeletal muscle and appears acceptable in 
older adults and other cancer groups (30-
33). 
Therefore, as a companion study to our 
previous works (34), the aim of this 
randomised controlled feasibility study was 
to evaluate the acceptability of a 
multi˗targeted approach encompassing a 
PRT protocol and nutritional 
supplementation (20 g EAA high in 
leucine) for lung cancer patients 
experiencing cancer cachexia.  
Materials and methods 
Trial design and changes 
Auckland’s Cancer Cachexia evaluating 
Resistance Training study (ACCeRT) is an 
open label, prospective, randomised 
controlled feasibility study. The study was 
registered by Australian New Zealand 
Clinical Trials (ACTRN12611000870954).  
Participants were randomised in a 1:2 ratio 
into one of the following two treatment 
arms: A) EPA and COX-2 inhibitor 
(international best supportive care); or B) 
EPA, COX-2 inhibitor and PRT (2 sessions 
per week) plus 20 g EAA high in leucine 
(treatment group). The study planned for 21 
participants to be enrolled for a 20 week 
investigation period. No treatment arm 
crossover was permitted during the study. 
All participants completing the 20 week 
study, irrespective of which arm they were 
randomised to, were offered to continue or 
receive study medication/training sessions 
under compassionate use.  
The following PRT exercise prescription 
was developed for this new population and 
was instigated in a non-linear method. PRT 
sessions were supervised by a clinical 
exercise physiologist. The planned PRT 
was broken into five  4 week phases that 
were periodised across the 20 weeks 
progressing in volume, intensity and 
complexity of exercise. Resistance was 
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provided via use of elasticated exercise 
bands (Theraband, USA), dumbbells or 
bodyweight. If the participant presented 
with disease-related symptoms, 
orthopaedic issues and/or bone metastasis, 
a conservative approach was taken to 
minimise risk and potential discomfort. 
This was achieved via a reduction of 
exercise loading and/or use of an alternative 
exercise to suit the participant’s needs. As 
indicated, participant’s heart rate and 
peripheral capillary oxygen saturation 
(SpO2) levels were monitored during 
exercise sessions. 
During phase 1, PRT consisted of 
fundamental upper and lower body 
resistance exercises in a seated position. 
Upper body exercises included iso-lateral 
chest press and row movements. Lower 
body exercises included iso-lateral knee 
flexion and extension. Exercises performed 
were prescribed at 1 set of up to 8 
repetitions, with initial intensity set at a 
Rate of Perceived Exertion (RPE) of “very 
light” to allow for familiarisation of the 
movements, which was to then be increased 
to an RPE of “light”. With phase 2 the 
above prescribed exercises were continued 
with the addition of a dumbbell bicep curl. 
Exercise volume was increased by adding a 
second set and intensity was increased to an 
RPE of “somewhat hard”. For phase 3, 
partial squat exercises were introduced and 
the upper body exercises were performed in 
a standing position. Exercise volume and 
intensity was set to be maintained. For 
phase 4, the exercise prescription was 
maintained however, with intensity was 
increased to an RPE of “hard”. During 
phase 5, the PRT intensity was maintained. 
Upon completion of phase 5 (20 weeks), 
compassionate PRT was offered with no 
further changes to the PRT prescription. 
Primary endpoint 
To determine the acceptability of a multi-
targeted approach of supportive care in 
cachectic NSCLC participants. Assessed by 
the analysis of a patient rated Likert scored 
questionnaire asking 10 questions on the 
acceptability of the above multi˗targeted 
approach, both at week 12 and week 20/end 
of trial (EOT) visit. 
Secondary endpoints 
To assess the trends in efficacy and safety 
of the above multi-targeted approach of 
supportive care in cachectic NSCLC 
participants. 
Efficacy was assessed by comparison 
between the two groups using the following 
data; 
1. Body composition assessed by 
bioelectrical impedance analysis 
(BIA). 
2. 3T Magnetic Resonance Imaging 
(MRI) total quadriceps muscle volume.  
3. Serum proinflammatory cytokine 
profiles analysing the ‘classic cachexia 
cytokines’ Interleukin-1β, Interleukin-
6 and Tumour Necrosis Factor-α (IL-
1β, IL-6 and TNF-α). 
4. Hand-grip strength assessed by hand 
grip dynamometry of the dominant 
hand. 
5. Leg strength assessed by isometric 
back/leg dynamometry (PE018 Back 
Dynamometer, Access Health), or 
from amended protocol by isometric 
force by customised chair and load cell. 
6. Compliance results analysed as 
percentage of total taken of study 
medication and attendance of study 
sessions. 
7. QOL and fatigue assessed by the 
following questionnaires; The 
Functional Assessment of 
Anorexia/Cachexia Therapy (FAACT 
physical well-being subscale (PWS)). 
The Multidimensional Fatigue 
Symptom Inventory-Short Form 
(MFSI-SF). World Health 
Organization Quality of Life-Brief 
(WHOQOL-BREF) overall QOL.  
8. Prognostic score assessed by 
laboratory values of albumin and C-
reactive protein (CRP) incorporated 
into the Glasgow Prognostic Score 
(GPS). 
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9. Performance status assessed by Eastern 
Cooperative Oncology Group 
Performance Status (ECOG-PS) and 
Karnofsky Score (KS).  
Safety was assessed by comparison 
between the two groups using the number 
of serious adverse events (SAEs) and 
changes on electrocardiogram (ECG) 
assessments.  
Trial changes 
Reasons for performing a feasibility study 
include testing the integrity of the 
components of the study in terms of 
treatments, follow-up assessments, testing 
questionnaires as well as gaining rates of 
consent, recruitment and retention, and 
selecting the primary outcome measure for 
the main study (35). The primary outcome 
in the ACCeRT study was the clinical 
acceptability of the multi-targeted approach 
in this specific population. This included 
the schedule of study 
intervention/medication and study visits, 
along with gaining experience around 
secondary outcomes in terms of the 
technical aspects of leg strength analysis 
and 3T MRI muscle analysis (36). 
Encapsulation 
The bolus ingestion of 20 g of EAA within 
a 250 ml non-caffeinated drink was tested 
and it was discovered that it had poor 
palatability. It was decided before the study 
commenced to change to an encapsulated 
form. Therefore, all participants received 
the total dose of 20 g of EAA high in 
leucine capsules (500 mg per ‘0’ sized 
gelatin capsule) for a total of 40 capsules 
per each PRT session over three days 
commencing 1 hour after PRT as per 
schedule (Table 1).
 
Table 1. Essential amino acid schedule utilised within the ACCeRT study. 
EAA (g) Number of capsules Time point 
4 g 8 1 hour post exercise 
4 g 8 Evening post exercise 
3 g 6 Day 2 - afternoon 
3 g 6 Day 2 - evening 
3 g 6 Day 3 - afternoon 
3 g 6 Day 3 - evening 
EAA; Essential Amino Acids. 
 
Leg strength dynamometry 
Participants’ leg strength analysis was to be 
performed at all study visits, and assessed 
by back/leg dynamometry of both legs. It 
was identified that it was difficult to 
maintain set joint angles during maximal 
isometric contraction in this population 
while using the back/leg dynamometer, and 
its use by non-exercise physiologist staff 
and participants had commented on the 
unacceptability of this equipment. In 
addition, there was safety concerns around 
its use in participants with spinal bone 
metastases, which had not been previously 
investigated; therefore, the presence of 
bone metastases was an exclusion for this 
study assessment. 
A change was made to utilise a customised 
extension rig (chair) with a 1kN (kilo 
Newton) load cell in series to measure 
isometric force. Maximum voluntary 
contraction (MVC) was carried out by 
clinical exercise physiologists, assessed 
over a period of 10 seconds with 
considerable verbal encouragement. 
Contractions were repeated three times at 1 
minute intervals. 
Participants sat in the customised rig (chair) 
and velcro straps were placed across the 
pelvis/waist, thighs and chest to minimise 
movement from joints other than the knee. 
The starting knee position was set to 90° 
flexion, with participants crossing their 
arms across the chest during the testing. 
Isometric force was assessed for either the 
right or left knee extensor (quadriceps 
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femoris) muscle group. A comfortable 
padded cuff was placed around the lower 
leg, just above the malleolus, and attached 
to a chain in series with the load cell (Figure 
1). The load cell output was amplified 
(RM044, Applied Measurement, Victoria, 
Australia) and sampled at 200 Hz (200 
samples per second) by a 64-bit A–D 
converter (PCI-6035E, National 
Instruments, TX, USA) connected to a 
personal computer. Load cell results gained 
initially in LabVIEW Measurement data 
(Labview, National Instruments, TX, USA) 
presented in Millivolts, kg and Newtons. 
The results were then converted into 
EXCEL software for analysis and the 
highest of the three attempts at each study 
visit recorded as the MVC. 
 
 
 
Figure 1. Pictures of a volunteer undergoing leg strength testing. 
 
Study drug dose reductions 
Some participants expressed that they 
found taking the study drug medication 
(EPA, COX-2 inhibitor, and EAA) 
unpalatable or just too large in quantity with 
other concomitant medication. It was 
decided to allow participants to dose reduce 
the quantity of study medication.  
Locations 
Cancer and Blood Services at Auckland 
City Hospital was the main referring centre 
for cancer patients. Geographically it 
covers North, East, South and West 
Auckland patients. Potential participants 
had turned the study down due to travelling 
distance and time to this location. 
Participants were now able to attend the 
PRT sessions at a centre nearest their 
location. 
Inclusion criteria 
The original inclusion criteria included 
participants that had ‘recently completed 
first-line platinum-based chemotherapy’. 
During recruitment it was identified that 
firstly, a percentage of patients were 
advised and received a non-platinum 
chemotherapy regimen, or radiotherapy 
alone to palliate symptoms. Secondly, 
publicly funded gefitinib was accessible to 
New Zealand patients (July 2012), along 
with private access to erlotinib or the 
compassionate use of the ALK inhibitor - 
crizotinib. The protocol was amended to 
include all participants who had received at 
least a first line anti-cancer treatment which 
could include either surgery, 
chemotherapy, radiotherapy and/or a 
targeted therapy. 
All the above amendments were deemed as 
being in line with the aims of carrying out a 
feasibility study.  
Guest participant 
The ACCeRT study was utilising a number 
of new techniques, new members of the 
research team, along with a new research 
location. It was decided to invite a 
participant onto the study as a ‘guest’ to 
identify any potential scheduling and 
technique issues prior to recruiting to the 
main study. The guest participant was a 
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New Zealand European 78 year old male, 
with stage IV squamous lung cancer of the 
left upper lobe (bone, adrenal, bilateral 
lung) diagnosed 875 days (2 years, 4 
months and 24 days) before study entry. He 
had received four previous lines of 
treatment. Baseline weight 92.5 kg reduced 
to 90.5 kg (-2.6% over 3 months). Total 
days on study 20 weeks (148 days), plus 
compassionate use up to 32 weeks (236 
days). Died 60 weeks (420 days) after 
enrolment. Received RT to the left chest 
during the last week on study 20 Gy in 5# 
during PRT 39, 40 and 41. Then 
commenced fifth line single-agent 
vinorelbine chemotherapy, for 2 cycles, 
with cycle 1, day 1 during PRT 63/64, and 
cycle 1 day 8 during PRT 65/66. Response 
evaluation criteria in solid tumours 
(RECIST) data, showed continued disease 
progression as detected by chest-x-ray in 
May and August 2012, and was later 
confirmed by CT in November 2012. 
Results  
Primary outcome 
The guest participant completed the 
acceptability questionnaire both at week 12 
and week 20/EOT study visits. EPA and 
COX-2 inhibitor (celecoxib) acceptability 
and palatability was scored high at 5 
‘strongly agree’ for both visits. PRT 
sessions and EAA acceptability/palatability 
also scored high at 5 for both study visits. 
The guest participant also scored 5 for the 
final question on wishing highly to continue 
with all the medication and exercise 
sessions. 
Compliance data showed EPA and COX-2 
inhibitor (celecoxib) 100% compliance, 
with PRT attendance of 100% up to weeks 
12 and 20 with a missed PRT session up to 
week 32. EAA compliance of 100%, 98.3% 
and 98.9% at weeks 12, 20 and 32 (missed 
two doses 1 x 8 g, 1 x 6 g = 14 g) 
respectively. These results indicate the high 
acceptability of the allocated multi-targeted 
regimen in the context of progressing 
NSCLC by the completion of a patient rated 
questionnaire and the 
compliance/attendance levels of the study 
medication and training sessions. The 
combination of EPA, COX-2 inhibitor 
(celecoxib), PRT sessions and EAA, were 
acceptable to the guest participant at the 
stated doses and sessions. The guest 
participant completed the 20 week study 
period and chose to continue with 
compassionate use of study medication and 
PRT sessions. 
Secondary outcomes 
A minor loss of BIA FFM from baseline 
was seen at weeks 12 and 20 with an overall 
change of -0.3 kg (˗0.5%) at week 20 (Table 
2). Total body weight change at week 12 of 
+0.1 kg (+0.1%), and of ˗4.5 kg (˗5%) at 
week 20. This indicates stable weight, then 
weight loss returned at week 20. 
Interestingly, this data indicates that while 
total body weight had decreased by almost 
5% at week 20, this was limited to only -
0.5% in FFM. From week 20 to week 32/3 
month compassionate use (CU) shows the 
progressing loss of both FFM and weight of 
˗4.9 kg (-8.8%) and ˗11.2 kg (-12.3%) 
respectively. Data shows the MRI total 
quadriceps muscle volume change from 
baseline to week 20/EOT of -178 cm3 (-
10.4%), indicating loss of total quadriceps 
muscle volume. The change from baseline 
in IL-6 levels of ˗0.86 pg/ml at week 12 and 
an increase of +4.16 pg/ml at week 20. With 
a corresponding increase in TNF-α levels of 
+2.87 pg/ml at week 12 and +1.73 pg/ml at 
week 20. Both levels of IL-6 and TNF-α 
remained relatively stable over 20 weeks, 
with decreased levels at week 32/3 month 
CU indicating a reduction in the 
proinflammatory cytokines. Hand-grip 
strength data demonstrates a change from 
baseline of -10 kg (˗30.3%) at week 12, 
indicating loss of muscle strength. This loss 
remained stable with -12 kg (-36.4%) at 
week 20. Leg strength data shows an 
increase in strength. This suggests that the 
PRT sessions did not assist in maintaining 
hand-grip strength, but possibly increased 
leg strength. 
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Albumin level data shows decreasing levels 
of -4 g/L at week 12 and -7 g/L at week 20. 
This indicates nutritional stability up to 
week 12 then decreasing nutrition at week 
20. CRP level data shows increasing levels 
of +25 g/L at week 12 and +65 g/L at week 
20, indicating progressing inflammation 
over study period to week 20. Both levels 
of albumin and CRP decreased at week 32/3 
month CU indicating a slight reduction in 
nutrition status, and decreasing 
inflammation. This could be attributed to 
the guest participant receiving single-agent 
vinorelbine chemotherapy during this 
period. 
 
Table 2. Guest participant results. 
 Baseline Week 12 Week 20 Week 32 
(3 month CU) 
BIA     
FFM (kg) 55.8 54.7 55.5 50.9 
Total Body Weight (kg) 90.8 90.9 86.3 79.6 
MRI     
Total quadriceps muscle volume (cm3) 1705  1527  
Proinflammatory cytokines     
IL-6 (pg/ml) 11.56 10.7 15.72 9.97 
TNF-α (pg/ml) 17.19 20.06 18.92 11.37 
Strength     
Hand grip (kg) 33 23 21  
Leg (Newtons) 941.8  1069.3  
Prognostic     
Albumin (g/L) 40 36 33 32 
CRP (mg/L) 30 55 95 83 
GPS 1 1 2 1 
Performance status     
ECOG-PS (KS) 1 (80) 1 (80) 1 (80) 1 (75) 
BIA; Bioelectrical Impedance Analysis, FFM; Fat Free Mass, MRI; Magnetic Resonance Imaging, IL-6; 
Interleukin-6, TNF-α; Tumour Necrosis Factor-alpha, CRP; C-Reactive Protein, GPS; Glasgow Prognostic Score, 
ECOG-PS; Eastern Cooperative Oncology Group Performance Status, KS; Karnofsky Performance Status, CU; 
Compassionate Use. 
 
FAACT-PWB data showed change of +2 
and +1, with MFSI˗SF physical scale a 
change of -1 and -1, and WHOQOL-BREF 
overall QOL score change of +0 and -2 at 
weeks 12 and week 20 respectively. All 
indicating that the guest participant’s 
physical well-being and QOL remained 
stable. 
Table 3 indicates that the guest participant 
either achieved or over-achieved the 
planned progression during phase 1 to IV, 
but then under-achieved during phase V, 
due to symptoms of progressive disease. 
The guest participant then achieved an 
adapted program during PRT from weeks 
41 to 68. Compassionate PRT was 
discontinued at week 33/PRT 68 due to 
SAE from chemotherapy. 
For safety, all participants received 
omeprazole 20 mg o.d. and received a 12-
lead ECG at baseline, week 12 and week 20. 
The guest participant was already 
prescribed diltiazem 120 mg o.d, and no 
significant changes were seen in ECG 
assessments throughout the study. One 
SAE was experienced while receiving 
compassionate use; grade 3 febrile 
neutropenia (neutropenia grade 4) and 
grade 2 constipation due to vinorelbine 
chemotherapy and infected dog bite. 
Discussion 
ACCeRT is the first to utilise a multi-
targeted regimen in the refractory cancer 
population and a comparison with other 
research studies cannot be made at this 
point. Similar studies that have 
implemented a multi-targeted approach 
include the randomised phase II feasibility 
trial of lung and pancreatic cancer patients 
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undergoing cycles III and IV of standard 
chemotherapy, randomised to standard care 
or oral nutritional supplements, anti-
inflammatory (celecoxib) and home-based 
aerobic (twice weekly) and resistance 
training (three time weekly) known as the 
Pre-MENAC study (37). This has been 
followed by the phase III MENAC study 
which randomises patients undergoing 
chemotherapy to either standard care or oral 
nutritional supplements, anti-inflammatory 
medication (ibuprofen) and home-based 
self-assisted exercise program, currently 
recruiting (38). Both of these trials are 
targeting early cachexia. It has been stated 
that the combination of physical inactivity, 
inflammation and poor nutritional status 
may prevent the reversal of weight and 
muscle loss, and that any intervention 
would be unlikely to see a reversal of the 
cachexia related symptoms within the last 
90 days of life (39). The above guest 
participant achieved 32 weeks on the 
ACCeRT regimen and, survived for a 
further 28 weeks post-end of compassionate 
use. These results indicate that patients may 
benefit from a multi-targeted approach in 
cachexia symptom management even 
during the late/refractory stage.  
 
Table 3. Guest participant progressive resistance training results. 
 
Phase I 
Weeks 
1 to 4 
Phase II 
Weeks 
5 to 8 
Phase III 
Weeks 
9 to 12 
Phase IV 
Weeks 
13 to 16 
Phase V 
Weeks 
17 to 20 
 
Phase VI 
Weeks 
21 to 24 
Phase VII 
Weeks 
25  to 28 
Phase VIII 
Weeks 
29 to 32 
 
PRT 
 1 to 8 
PRT 
 9 to 16 
PRT  
17 to 24 
PRT 
 25 to 32 
PRT  
33 to 40 
 
PRT 
 41 to 48 
PRT 
 49 to 56 
PRT  
57 to 64 
PLANNED 
‘very light’ 
to ‘light’ 
BORG 8-11 
‘somewhat hard’ 
BORG 12-13 
‘hard’ 
BORG 14-15 
 
‘somewhat hard’ 
BORG 12-13 
UPPER 
achieved 
BORG 11 
over-
achieved 
BORG 13 
achieved 
BORG 13 
over-
achieved 
BORG 15 
under- 
achieved 
BORG 13 
 
achieved 
BORG 
13 
achieved 
BORG 13 
achieved 
BORG 13 
LOWER 
over-
achieved 
BORG 12 
over-
achieved 
BORG 13 
achieved 
BORG 13 
over-
achieved 
BORG 15 
under- 
achieved 
BORG 13 
 
achieved 
BORG 
13 
achieved 
BORG 13 
achieved 
BORG 13 
PRT; Progressive Resistance Training. 
 
Conclusions 
The ACCeRT study protocol received 
minor amendments responding to both 
study participants and research team 
members to allow optimization of the 
planned study protocol. The guest 
participant results showed acceptability to 
the multi-targeted schedule with high levels 
rated in both the questionnaire and high 
compliance with study medication and PRT 
session attendance. These amendments 
were utilized within the main study, which 
has completed recruitment and full study 
results in press. Collectively, the results for 
the guest participant demonstrate efficacy 
in stabilising FFM in the context of 
decreasing total body weight, potentially 
via a muscle protein-sparing effect. 
Furthermore, stable FAACT-PWB, MFSI-
SF physical and WHOQOL˗BREF QOL 
scores were reported at week 20, all during 
documented disease progression now 
termed refractory cachexia. The current 
findings provide preliminary support for the 
potential health-related benefits associated 
with combined PRT and EAA ingestion, 
however caution is warranted in the 
interpretation of the results as they are 
limited to one participant. 
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